Figure 1.
![Treatment with eltanexor leads to alterations in apoptotic proteins, and combination with venetoclax synergizes to inhibit growth of AML cells in vitro. Western blot analysis of MV-4-11 and MOLM-13 cells after 24 hours of treatment with dimethyl sulfoxide (DMSO [D]) or a dose titration of eltanexor (ELTA) to determine protein levels of XPO1, p53, MCL1, and cleaved caspase 3. Actin was used as a loading control. Vertical line indicates different exposures because of varying levels of endogenous XPO1.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/4/3/10.1182_bloodadvances.2019000359/2/advancesadv2019000359f1.png?Expires=1742739519&Signature=a~K-6H-C5sDZpVlqLXIkCLPcT-PkwuMD-B5ROPJ-tkOFMrE3VCt5UHq8Tzcq8O4BLIbdI5-uUe1i2-F3K5fOmQTVEZNyJ7VEwlkDR9WvGXQXm0e5QF8eX76trimRziHf5SReyXAInLdERH0eeACCW~oPWUWhk2PBXtLrtv8DeD4mPaVy6k0DnrVYTks9cj3MirLbkix8ElJzeXam~bgMKtnRkSIXzA-n~oh7n1hWg9mJTb5w0JwJcbtVs5njf-jfanG~Dmt2aI7SImm1TdOXHd7C3gKWxQe7D~AlE2~Zd8r-5Y7v0tOpngEn0euTqh~HjNEkxqauWPMO~5oeLPpwyg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Treatment with eltanexor leads to alterations in apoptotic proteins, and combination with venetoclax synergizes to inhibit growth of AML cells in vitro. Western blot analysis of MV-4-11 and MOLM-13 cells after 24 hours of treatment with dimethyl sulfoxide (DMSO [D]) or a dose titration of eltanexor (ELTA) to determine protein levels of XPO1, p53, MCL1, and cleaved caspase 3. Actin was used as a loading control. Vertical line indicates different exposures because of varying levels of endogenous XPO1.